Calitii, a Synechron company, secures Managed Services contract with BridgeBio to drive ServiceNow operational excellence

Calitii, a Synechron company and global IT consultancy, today announced it has secured a contract with BridgeBio, a biopharmaceutical company, to provide comprehensive ServiceNow Managed Services. The partnership builds on the greenfield ServiceNow IT Service Management implementation Calitii carried out last year to the day-to-day management, proactive maintenance, and continuous optimisation of BridgeBio’s ServiceNow platform.  Under the terms of the agreement, Calitii will act as a strategic extension of BridgeBio’s internal IT team. By providing a fully Managed Service, Calitii will ensure the ServiceNow platform remains agile, secure, and aligned with BridgeBio’s evolving business needs.  Patrick O’Connor, CEO at Calitii, a Synechron company, said: “Managing a complex ServiceNow environment demands a proactive approach, constant evolution and strategic insight to stay ahead of business demands. We are thrilled to deepen our relationship with BridgeBio through this Managed Services agreement. Our focus goes beyond the ‘break-fix’ cycle. We are committed to driving innovation and continual improvements, ensuring BridgeBio’s platform achieves sustained value, improved compliance, enhanced security, high performance, and operational scalability.”    Nick Keenan, SVP, Head of IT at BridgeBio, said: “As BridgeBio continues to scale, it is vital that our digital infrastructure remains robust and efficient. Appointing Calitii, a Synechron company, to help manage our ServiceNow platform allows us to leverage their certified and experienced team’s industry knowledge and technical expertise in highly regulated markets.  We were impressed by their proactive approach in identifying and driving continual service improvements to achieve platform efficiency, security, and reliability. This partnership will deliver excellent platform performance, continuous innovation and business value, driving productivity across our global operations and supporting our strategic growth objectives.” The key solution elements of the ServiceNow Managed Services that Calitii, a Synechron company, will deliver include:  

• Proactive identification and implementation of service improvements to optimise platform efficiency, security and reliability. 
• Certified and experienced support team: management of enquiries, incidents, problems, enhancements and requests.  
• Strategic advisory: long-term roadmap and strategy guidance sessions to ensure full value is leveraged from the platform, including the deployment of new features and the integration of AI capabilities. 
• Platform maintenance and proactive management: upgrades, patching, health-checks and security assessments. 
• Operational support: 24 x 7 help desk for user issues and bug fixes. 

About Calitii     Calitii is part of Synechron, a leading global digital transformation consulting firm.   Synechron announced its acquisition of Calitii in October 2025.   As a ServiceNow Consulting and Implementation Elite Partner, Calitii is focused on delivering digital transformation and critical change at scale for enterprises operating within highly regulated markets. Combining ServiceNow excellence, world-class business understanding and enterprise architecture capabilities, Calitii utilises experienced practitioner teams to drive effective change across business silos, transforming operational efficiencies and agility for large scale enterprises. Established in November 2023, it offers significant expertise in the life sciences, banking, insurance, energy and utilities sectors. For more information visit calitii.com and follow via LinkedIn and X.        About BridgeBio Pharma, Inc.   BridgeBio Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow via LinkedIn, Twitter and Facebook.